{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:03:20Z","timestamp":1789765400248,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.drudis.2026.104798","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:38:50Z","timestamp":1788676730000},"page":"104798","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The shelved pipeline: AI can find strategically abandoned medicines and bring them to patients"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5031-6244","authenticated-orcid":false,"given":"Ore","family":"Arowojolu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104798_b0005","unstructured":"PR Newswire. Isomorphic Labs secures $2.1 billion funding to scale its AI drug design engine. Published 12 May 2026. Accessed 14 June 2026. https:\/\/www.prnewswire.com\/news-releases\/isomorphic-labs-secures-2-1-billion-funding-to-scale-its-ai-drug-design-engine-302769674.html."},{"key":"10.1016\/j.drudis.2026.104798_b0010","unstructured":"Taylor NP. Chai brews up $400M series C to fuel AI molecule models used by Lilly, Novartis and Pfizer. Published 14 July 2026. Accessed 25 August 2026. https:\/\/www.fiercebiotech.com\/biotech\/chai-brews-400m-series-c-fuel-ai-used-lilly-novartis-and-pfizer."},{"key":"10.1016\/j.drudis.2026.104798_b0015","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1038\/s41591-025-03743-2","article-title":"A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial","volume":"31","author":"Xu","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2026.104798_b0020","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/d41573-025-00208-6","article-title":"Analysis of phase II and phase III clinical trial terminations from 2013 to 2023","volume":"25","author":"Bowling","year":"2026","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104798_b0025","unstructured":"BioSpace. More than one-third of biotechs have under a year of cash left, EY finds. Published 18 June 2025. Accessed 7 July 2026. https:\/\/www.biospace.com\/business\/more-than-one-third-of-biotechs-have-under-a-year-of-cash-left-ey-finds."},{"key":"10.1016\/j.drudis.2026.104798_b0030","unstructured":"Evaluate. Portfolio tactics to scale the $300bn patent cliff. Published 8 October 2025. Accessed 7 July 2026. https:\/\/www.evaluate.com\/thought-leadership\/portfolio-tactics-to-scale-the-300bn-patent-cliff\/."},{"key":"10.1016\/j.drudis.2026.104798_b0035","unstructured":"Applied Clinical Trials. Tufts Center for the Study of Drug Development Reasons for clinical failures by phase. Published 2013. Accessed 14 June 2026. https:\/\/www.appliedclinicaltrialsonline.com\/view\/reasons-clinical-failures-phase."},{"key":"10.1016\/j.drudis.2026.104798_b0040","unstructured":"Citeline. Pharma R&D Annual Review 2026. Figure 23: growth\/decline in pipeline size for top 10 companies over the past five years (p. 53). Accessed 14 June 2026. https:\/\/www.citeline.com\/rd26."},{"key":"10.1016\/j.drudis.2026.104798_b0045","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1186\/s12913-022-08272-z","article-title":"Drug repurposing: a systematic review on root causes, barriers and facilitators","volume":"22","author":"Krishnamurthy","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.drudis.2026.104798_b0050","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","article-title":"Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database","volume":"28","author":"Nguengang Wakap","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.drudis.2026.104798_b0055","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/s41431-024-01604-z","article-title":"Time to diagnosis and determinants of diagnostic delays of people living with a rare disease: results of a Rare Barometer retrospective patient survey","volume":"32","author":"Faye","year":"2024","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.drudis.2026.104798_b0060","unstructured":"Roivant Sciences. Roivant and Priovant announce positive phase 3 VALOR study results for brepocitinib in dermatomyositis. Published 17 September 2025. Accessed 14 June 2026. https:\/\/investor.roivant.com\/news-releases\/news-release-details\/roivant-and-priovant-announce-positive-phase-3-valor-study\/."},{"key":"10.1016\/j.drudis.2026.104798_b0065","unstructured":"BioPharma Dive. Roche to gain gut disease drug in $7.1B deal for Roivant subsidiary. Published 23 October 2023. Accessed 14 June 2026. https:\/\/www.biopharmadive.com\/news\/roivant-roche-pfizer-tl1a-telavant-acquire-ibd-drug\/687882\/."},{"key":"10.1016\/j.drudis.2026.104798_b0070","unstructured":"Axios. Pfizer spins out shelved experimental drugs. Published 25 September 2017. Accessed 14 June 2026. https:\/\/www.axios.com\/2017\/12\/15\/pfizer-spins-out-shelved-experimental-drugs-1513305739."},{"key":"10.1016\/j.drudis.2026.104798_b0075","unstructured":"US Food and Drug Administration. FDA approves nirogacestat for desmoid tumors. Published 28 November 2023. Accessed 14 June 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nirogacestat-desmoid-tumors."},{"key":"10.1016\/j.drudis.2026.104798_b0080","unstructured":"GlobeNewswire. SpringWorks Therapeutics Announces FDA Approval of GOMEKLI\u2122 (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN. Published 11 February 2025. Accessed 14 June 2026. https:\/\/www.globenewswire.com\/news-release\/2025\/02\/12\/3024681\/0\/en\/UPDATE-SpringWorks-Therapeutics-Announces-FDA-Approval-of-GOMEKLI-mirdametinib-for-the-Treatment-of-Adult-and-Pediatric-Patients-with-NF1-PN.html."},{"key":"10.1016\/j.drudis.2026.104798_b0085","unstructured":"GSK. GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease. Published 14 May 2025. Accessed 14 June 2026. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-to-acquire-efimosfermin-a-phase-iii-ready-potential-best-in-class-specialty-medicine-to-treat-and-prevent-progression-of-steatotic-liver-disease-sld\/."},{"key":"10.1016\/j.drudis.2026.104798_b0090","unstructured":"Every Cure. Every Cure to receive $48.3M from ARPA-H to develop AI-driven platform to revolutionize future of drug development and repurposing. Published 28 February 2024. Accessed 7 July 2026. https:\/\/everycure.org\/every-cure-to-receive-48-3m-from-arpa-h-to-develop-ai-driven-platform-to-revolutionize-future-of-drug-development-and-repurposing\/."},{"key":"10.1016\/j.drudis.2026.104798_b0095","unstructured":"Nature Reviews Drug Discovery. FDA approves first schizophrenia drug with new mechanism of action since 1950s. Published 27 September 2024. Accessed 14 June 2026. https:\/\/www.nature.com\/articles\/d41573-024-00155-8."},{"key":"10.1016\/j.drudis.2026.104798_b0100","unstructured":"Van de Vyver B, Berghauser Pont L, Parekh R. External innovation: biopharma dealmaking to boost R&D productivity. McKinsey & Company Website. Published 2025. Accessed 7 July 2026. https:\/\/www.mckinsey.com\/industries\/life-sciences\/our-insights\/external-innovation-biopharma-dealmaking-to-boost-r-and-d-productivity."},{"key":"10.1016\/j.drudis.2026.104798_b0105","unstructured":"GlobeNewswire. Roivant announces expansion of brepocitinib development program and phase 3 study results for batoclimab in thyroid eye disease. Published 2 April 2026. Accessed 14 June 2026. https:\/\/www.globenewswire.com\/news-release\/2026\/04\/02\/3267157\/34323\/en\/Roivant-Announces-Expansion-of-Brepocitinib-Development-Program-with-New-Phase-2b-3-Trial-in-Lichen-Planopilaris-LPP-and-Phase-3-Study-Results-for-Batoclimab-in-Thyroid-Eye-Disease.html."},{"key":"10.1016\/j.drudis.2026.104798_b0110","unstructured":"Fierce Biotech. BridgeBio CEO Kumar its \u2018hub-and-spoke\u2019 model and where else it could work. Published 10 June 2020. Accessed 7 July 2026. https:\/\/www.fiercebiotech.com\/biotech\/bio-bridgebio-ceo-kumar-its-hub-and-spoke-model-and-where-else-it-could-work."},{"key":"10.1016\/j.drudis.2026.104798_b0115","unstructured":"PR Newswire. Formation Bio secures $372MM Series D funding to grow drug pipeline and continue expanding AI-driven drug development platform. Published 26 June 2024. Accessed 7 July 2026. https:\/\/www.prnewswire.com\/news-releases\/formation-bio-secures-372mm-series-d-funding-to-grow-drug-pipeline-and-continue-expanding-ai-driven-drug-development-platform-302182347.html."},{"key":"10.1016\/j.drudis.2026.104798_b0120","unstructured":"McKinsey & Company. The emerging epicenter: Asia\u2019s role in biopharma\u2019s future. Published 7 January 2026. Accessed 14 June 2026. https:\/\/www.mckinsey.com\/industries\/life-sciences\/our-insights\/the-emerging-epicenter-asias-role-in-biopharmas-future."},{"key":"10.1016\/j.drudis.2026.104798_b0125","unstructured":"Information Technology and Innovation Foundation. China has surpassed the US in the number of drug clinical trials. Published 9 June 20Accessed 14 June 2026. https:\/\/itif.org\/publications\/2025\/06\/09\/china-surpassed-us-number-drug-clinical-trials-1-100-more\/."},{"key":"10.1016\/j.drudis.2026.104798_b0130","doi-asserted-by":"crossref","unstructured":"Barwick PJ, Xia H, Xia T. From free rider to innovator: the rise of China\u2019s drug development. NBER Working Paper 34977. Published March 2026. Accessed 7 July 2026. https:\/\/www.nber.org\/papers\/w34977.","DOI":"10.3386\/w34977"},{"key":"10.1016\/j.drudis.2026.104798_b0135","unstructured":"South China Morning Post. Chinese biotechs strike a record US$136 billion in out-licensing deals in 2025. Published 8 January 2026. Accessed 14 June 2026. https:\/\/www.scmp.com\/business\/china-business\/article\/3339011\/chinese-drug-makers-strike-record-us136-billion-out-licensing-deals-2025."},{"key":"10.1016\/j.drudis.2026.104798_b0140","unstructured":"General Atlantic. Verdiva Bio, a new clinical-stage cardiometabolic company, launches with over $410M in Series A financing to advance next-generation therapies. Published 9 January 2025. Accessed 7 July 2026. https:\/\/www.generalatlantic.com\/media-article\/verdiva-bio-a-new-clinical-stage-cardiometabolic-company-launches-with-over-410m-in-series-a-financing-to-advance-next-generation-therapies\/."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:18:21Z","timestamp":1789762701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626002035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1359644626002035"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104798","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The shelved pipeline: AI can find strategically abandoned medicines and bring them to patients","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104798","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104798"}}